Regulation of MMPs during melanoma progression: From genetic to epigenetic

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 773-782

  Frank, Antonicelli ^a   David, Vallerand ^a   Aurélie, Trussardi Regnier ^b   Florent, Grange ^a,c   William, Hornebeck ^a   Philippe, Bernard ^a,c  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b CNRS   (France)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

Cancer; Epigenetic; Lymphocyte; Melanoma; MMP

Indexed keywords

BRG1 PROTEIN; CHEMOKINE RECEPTOR CXCR4; ENTINOSTAT; GELATINASE B; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 8; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUTROPHIL COLLAGENASE; PROTEIN FOS; SMAD PROTEIN; STAT PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VALPROIC ACID;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; DNA METHYLATION; ENZYME BLOOD LEVEL; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; IMMUNOCOMPETENT CELL; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SUMOYLATION;

EID: 84866370600     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650228     Document Type: Article

References (86)

1. Payette, M. J.; Katz, M., 3rd; Grant-Kels, J. M. Melanoma prognostic factors found in the dermatopathology report, Clin. Dermatol., 2009, 27, 53-74.
2. Tchen, T.; Leonard, F.; Derancourt, C.; Perceau, G.; Goutorbe, C.; Reguiai, Z.; Bernard, P.; Grange, F. Long-term survivors in stage IV melanoma: a regional population-based study in France, Eur. J. Dermatol., 2009, 19, 38-43.
3. Vaisanen, A. H.; Kallioinen, M.; Turpeenniemi-Hujanen, T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma, Hum. Pathol., 2008, 39, 377-385.
4. Klein, T.; Bischoff, R. Physiology and pathophysiology of matrix metalloproteases, Amino Acids. 2010, 41(2):271-290.
5. Sun, J. Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells, J. Signal. Transuct., 2010, 2010, 985132.
6. Hornebeck, W.; Emonard, H.; Monboisse, J. C.; Bellon, G. Matrixdirected regulation of pericellular proteolysis and tumor progression, Semin. Cancer Biol., 2002, 12, 231-241.
7. Hofmann, U. B.; Eggert, A. A.; Blass, K.; Brocker, E. B.; Becker, J. C. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma, Arch. Dermatol. Res., 2005, 297, 154-160.
8. Hofmann, U. B.; Westphal, J. R.; Zendman, A. J.; Becker, J. C.; Ruiter, D. J.; van Muijen, G. N. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression, J. Pathol., 2000, 191, 245-256.
9. Benbow, U.; Schoenermark, M. P.; Mitchell, T. I.; Rutter, J. L.; Shimokawa, K.; Nagase, H.; Brinckerhoff, C. E. A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen, J. Biol. Chem., 1999, 274, 25371-25378.
10. Nikkola, J.; Vihinen, P.; Vuoristo, M. S.; Kellokumpu-Lehtinen, P.; Kahari, V. M.; Pyrhonen, S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma, Clin. Cancer. Res., 2005, 11, 5158-5166.
11. Vaisanen, A.; Kuvaja, P.; Kallioinen, M.; Turpeenniemi-Hujanen, T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53, Hum. Pathol., 2011, 42(8), 1103-1111
12. Ntayi, C.; Labrousse, A. L.; Debret, R.; Birembaut, P.; Bellon, G.; Antonicelli, F.; Hornebeck, W.; Bernard, P. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein, J. Invest. Dermatol., 2004, 122, 256-265.
13. Kondratiev, S.; Gnepp, D. R.; Yakirevich, E.; Sabo, E.; Annino, D. J.; Rebeiz, E.; Laver, N. V. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas, Hum. Pathol., 2008, 39, 337-343.
14. Rey, M. C.; Bonamigo, R. R.; Cartell, A.; Furian, R.; Bonfa, R. MMP-2 and TIMP-2 in Cutaneous Melanoma: Association With Prognostic Factors and Description in Cutaneous Metastases, Am. J. Dermatopathol., 2011, 33, 413-414.
15. Giricz, O.; Lauer, J. L.; Fields, G. B. Variability in melanoma metalloproteinase expression profiling, J. Biomol. Tech., 2010, 21, 194-204.
16. Giricz, O.; Lauer, J. L.; Fields, G. B. Comparison of metalloproteinase protein and activity profiling, Anal. Biochem., 2011, 409, 37-45.
17. Debret, R.; Le Naour, R. R.; Sallenave, J. M.; Deshorgue, A.; Hornebeck, W. G.; Guenounou, M.; Bernard, P.; Antonicelli, F. D. Elastin fragments induce IL-1beta upregulation via NF-kappaB pathway in melanoma cells, J. Invest. Dermatol., 2006, 126, 1860-1868.
18. Pasco, S.; Han, J.; Gillery, P.; Bellon, G.; Maquart, F. X.; Borel, J. P.; Kefalides, N. A.; Monboisse, J. C. A specific sequence of the noncollagenous domain of the alpha3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells, Cancer Res., 2000, 60, 467-473.
19. Pasco, S.; Monboisse, J. C.; Kieffer, N. The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha Vbeta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation, J. Biol. Chem., 2000, 275, 32999-33007.
20. Brezillon, S.; Zeltz, C.; Schneider, L.; Terryn, C.; Vuillermoz, B.; Ramont, L.; Perrau, C.; Pluot, M.; Diebold, M. D.; Radwanska, A.; Malicka-Blaszkiewicz, M.; Maquart, F. X.; Wegrowski, Y. Lumican inhibits B16F1 melanoma cell lung metastasis, J. Physiol. Pharmacol., 2009, 60 (Suppl 4), 15-22.
21. Brezillon, S.; Radwanska, A.; Zeltz, C.; Malkowski, A.; Ploton, D.; Bobichon, H.; Perreau, C.; Malicka-Blaszkiewicz, M.; Maquart, F. X.; Wegrowski, Y. Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes, Cancer Lett., 2009, 283, 92-100.
22. Antonicelli, F.; Bellon, G.; Debelle, L.; Hornebeck, W. Elastinelastases and inflamm-aging, Curr. Top. Dev. Biol., 2007, 79, 99-155.
23. Itoh, T.; Tanioka, M.; Matsuda, H.; Nishimoto, H.; Yoshioka, T.; Suzuki, R.; Uehira, M. Experimental metastasis is suppressed in MMP-9-deficient mice, Clin. Exp. Metastasis, 1999, 17, 177-181.
24. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression, Nat. Rev. Cancer, 2002, 2, 161-174.
25. Melnikova, V. O.; Bar-Eli, M. Inflammation and melanoma metastasis, Pigment Cell Melanoma Res., 2009, 22, 257-267.
26. van den Steen, P. E.; Proost, P.; Wuyts, A.; van Damme, J.; Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAPIII, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact, Blood, 2000, 96, 2673-2681.
27. Lemjabbar, H.; Gosset, P.; Lamblin, C.; Tillie, I.; Hartmann, D.; Wallaert, B.; Tonnel, A. B.; Lafuma, C. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus, Am J. Respir. Crit. Care Med., 1999, 159, 1298-1307.
28. Bar-Eli, M. Role of interleukin-8 in tumor growth and metastasis of human melanoma, Pathobiology, 1999, 67, 12-18.
29. Voronov, E.; Shouval, D. S.; Krelin, Y.; Cagnano, E.; Benharroch, D.; Iwakura, Y.; Dinarello, C. A.; Apte, R. N. IL-1 is required for tumor invasiveness and angiogenesis, Proc. Natl. Acad. Sci. U S A, 2003, 100, 2645-2650.
30. Gansbacher, B.; Bannerji, R.; Daniels, B.; Zier, K.; Cronin, K.; Gilboa, E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity, Cancer Res., 1990, 50, 7820-7825.
31. Gansbacher, B.; Zier, K.; Daniels, B.; Cronin, K.; Bannerji, R.; Gilboa, E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity, J. Exp. Med., 1990, 172, 1217-1224.
32. Baranek, T.; Debret, R.; Antonicelli, F.; Lamkhioued, B.; Belaaouaj, A.; Hornebeck, W.; Bernard, P.; Guenounou, M.; Le Naour, R. Elastin receptor (spliced galactosidase) occupancy by elastin peptides counteracts proinflammatory cytokine expression in lipopolysaccharide-stimulated human monocytes through NFkappaB down-regulation, J. Immunol., 2007, 179, 6184-6192.
33. Debret, R.; Antonicelli, F.; Theill, A.; Hornebeck, W.; Bernard, P.; Guenounou, M.; Le Naour, R. Elastin-derived peptides induce a Thelper type 1 polarization of human blood lymphocytes, Arterioscler Thromb. Vasc. Biol., 2005, 25, 1353-1358.
34. Yan, C.; Boyd, D. D. Regulation of matrix metalloproteinase gene expression, J. Cell Physiol., 2007, 211, 19-26.
35. Fanjul-Fernandez, M.; Folgueras, A. R.; Cabrera, S.; Lopez-Otin, C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models, Biochim. Biophys. Acta, 2010, 1803, 3-19.
36. Clark, I. M.; Swingler, T. E.; Sampieri, C. L.; Edwards, D. R. The regulation of matrix metalloproteinases and their inhibitors, Int. J. Biochem. Cell Biol., 2008, 40, 1362-1378.
37. Hofmann, U. B.; Houben, R.; Brocker, E. B.; Becker, J. C. Role of matrix metalloproteinases in melanoma cell invasion, Biochimie, 2005, 87, 307-314.
38. Kahari, V. M.; Saarialho-Kere, U. Matrix metalloproteinases in skin, Exp. Dermatol., 1997, 6, 199-213.
39. Vincenti, M. P.; Brinckerhoff, C. E. Signal transduction and celltype specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you?, J. Cell Physiol., 2007, 213, 355-364.
40. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era, Nat. Rev. Cancer, 2002, 2, 657-672.
41. Boukerche, H.; Su, Z. Z.; Emdad, L.; Sarkar, D.; Fisher, P. B. Mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB, Cancer Res., 2007, 67, 1812-1822.
42. Benbow, U.; Tower, G. B.; Wyatt, C. A.; Buttice, G.; Brinckerhoff, C. E. High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2 mitogen-activated protein kinases in VMM5 melanoma cells, J. Cell Biochem., 2002, 86, 307-319.
43. Rutter, J. L.; Mitchell, T. I.; Buttice, G.; Meyers, J.; Gusella, J. F.; Ozelius, L. J.; Brinckerhoff, C. E. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription, Cancer Res., 1998, 58, 5321-5325.
44. Cotignola, J.; Reva, B.; Mitra, N.; Ishill, N.; Chuai, S.; Patel, A.; Shah, S.; Vanderbeek, G.; Coit, D.; Busam, K.; Halpern, A.; Houghton, A.; Sander, C.; Berwick, M.; Orlow, I. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma, BMC. Med. Genet., 2007, 8, 8-10.
45. Cotignola, J.; Roy, P.; Patel, A.; Ishill, N.; Shah, S.; Houghton, A.; Coit, D.; Halpern, A.; Busam, K.; Berwick, M.; Orlow, I. Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression, J. Negat. Results Biomed, 2007, 24, 6-9.
46. Banerji, A.; Das, S.; Chatterjee, A. Culture of human A375 melanoma cells in the presence of fibronectin causes expression of MMP-9 and activation of MMP-2 in culture supernatants, J. Environ. Pathol. Toxicol. Oncol., 2008, 27, 135-145.
47. Philip, S.; Kundu, G. C. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways, J. Biol. Chem., 2003, 278, 14487-14497.
48. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat. Cell. Biol., 2000, 2, 737-744.
49. Sheu, B. C.; Hsu, S. M.; Ho, H. N.; Lien, H. C.; Huang, S. C.; Lin, R. H. A novel role of metalloproteinase in cancer-mediated immunosuppression, Cancer Res., 2001, 61, 237-242.
50. Chakrabarti, S.; Patel, K. D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology, Exp. Lung Res., 2005, 31, 599-621.
51. Clemente, C. G.; Mihm, M. C., Jr.; Bufalino, R.; Zurrida, S.; Collini, P.; Cascinelli, N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, 1996, 77, 1303-1310.
52. Howell, P. M., Jr.; Liu, S.; Ren, S.; Behlen, C.; Fodstad, O.; Riker, A. I. Epigenetics in human melanoma, Cancer Control, 2009, 16, 200-218.
53. Fuks, F. DNA methylation and histone modifications: teaming up to silence genes, Curr. Opin. Genet. Dev., 2005, 15, 490-495.
54. Campos, A. C.; Molognoni, F.; Melo, F. H.; Galdieri, L. C.; Carneiro, C. R.; D'Almeida, V.; Correa, M.; Jasiulionis, M. G. Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation, Neoplasia, 2007, 9, 1111-1121.
55. Chicoine, E.; Esteve, P. O.; Robledo, O.; van Themsche, C.; Potworowski, E. F.; St-Pierre, Y. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression, Biochem. Biophys. Res. Commun., 2002, 297, 765-772.
56. Couillard, J.; Demers, M.; Lavoie, G.; St-Pierre, Y. The role of DNA hypomethylation in the control of stromelysin gene expression, Biochem. Biophys. Res. Commun., 2006, 342, 1233-1239.
57. Poplineau, M.; Dufer, J.; Antonicelli, F.; Trussardi-Regnier, A. Epigenetic regulation of proMMP-1 expression in the HT1080 human fibrosarcoma cell line, Int. J. Oncol., 2011, 38(6):1713-1718.
58. Ricca, T. I.; Liang, G.; Suenaga, A. P.; Han, S. W.; Jones, P. A.; Jasiulionis, M. G. Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation, Transl. Oncol., 2009, 2, 329-340.
59. Sudarsanam, P.; Winston, F. The Swi/Snf family nucleosomeremodeling complexes and transcriptional control, Trends Genet., 2000, 16, 345-351.
60. Berger, S. L. Histone modifications in transcriptional regulation, Curr. Opin. Genet. Dev., 2002, 12, 142-148.
61. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors, Chem. Biol., 2002, 9, 3-16.
62. Marmorstein, R. Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases, Biochem. Soc. Trans., 2004, 32, 904-909.
63. Marmorstein, R. Structure of histone deacetylases: insights into substrate recognition and catalysis, Structure, 2001, 9, 1127-1133.
64. Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy, Cancer Lett., 2008, 269, 7-17.
65. Kim, H. J.; Bae, S. C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs, Am. J. Transl. Res., 2011, 3, 166-179.
66. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma, J. Clin. Oncol., 2005, 23, 3912-3922.
67. Klisovic, D. D.; Klisovic, M. I.; Effron, D.; Liu, S.; Marcucci, G.; Katz, S. E. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma, Melanoma Res., 2005, 15, 147-153.
68. Papi, A.; Ferreri, A. M.; Rocchi, P.; Guerra, F.; Orlandi, M. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells, Anticancer Res., 2010, 30, 535-540.
69. Ganesan, S.; Faris, A. N.; Comstock, A. T.; Chattoraj, S. S.; Chattoraj, A.; Burgess, J. R.; Curtis, J. L.; Martinez, F. J.; Zick, S.; Hershenson, M. B.; Sajjan, U. S. Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression, Respir. Res., 2010, 11, 131.
70. Debret, R.; Brassart-Pasco, S.; Lorin, J.; Martoriati, A.; Deshorgue, A.; Maquart, F. X.; Hornebeck, W.; Rahman, I.; Antonicelli, F. Ceramide inhibition of MMP-2 expression and human cancer bronchial cell invasiveness involve decreased histone acetylation, Biochim. Biophys. Acta., 2008, 1783, 1718-1727.
71. Ailenberg, M.; Silverman, M. Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression, Biochem. Biophys. Res. Commun., 2002, 298, 110-115.
72. Ailenberg, M.; Silverman, M. Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy, Biochem. Biophys. Res. Commun., 2003, 302, 181-185.
73. Milutinovic, S.; D'Alessio, A. C.; Detich, N.; Szyf, M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes, Carcinogenesis, 2007, 28, 560-571.
74. Ito, T.; Yamauchi, M.; Nishina, M.; Yamamichi, N.; Mizutani, T.; Ui, M.; Murakami, M.; Iba, H. Identification of SWI.SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers, J. Biol. Chem., 2001, 276, 2852-2857.
75. Saladi, S. V.; Keenen, B.; Marathe, H. G.; Qi, H.; Chin, K. V.; de la Serna, I. L. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness, Mol. Cancer., 2010, 9, 280.
76. Keenen, B.; Qi, H.; Saladi, S. V.; Yeung, M.; de la Serna, I. L. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma, Oncogene, 2010, 29, 81-92.
77. Vachtenheim, J.; Ondrusova, L.; Borovansky, J. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells, Biochem. Biophys. Res. Commun., 2010, 392, 454-459.
78. Ma, Z.; Shah, R. C.; Chang, M. J.; Benveniste, E. N. Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription, Mol. Cell. Biol., 2004, 24, 5496-5509.
79. Gregoire, S.; Xiao, L.; Nie, J.; Zhang, X.; Xu, M.; Li, J.; Wong, J.; Seto, E.; Yang, X. J. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2, Mol. Cell. Biol., 2007, 27, 1280-1295.
80. Ha, C. H.; Wang, W.; Jhun, B. S.; Wong, C.; Hausser, A.; Pfizenmaier, K.; McKinsey, T. A.; Olson, E. N.; Jin, Z. G. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis, J. Biol. Chem., 2008, 283, 14590-14599.
81. Chang, S.; Young, B. D.; Li, S.; Qi, X.; Richardson, J. A.; Olson, E. N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10, Cell, 2006, 126, 321-334.
82. Ha, C. H.; Jhun, B. S.; Kao, H. Y.; Jin, Z. G. VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis, Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1782-1788.
83. Seftor, E. A.; Meltzer, P. S.; Kirschmann, D. A.; Margaryan, N. V.; Seftor, R. E.; Hendrix, M. J. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment, J. Cell. Mol. Med., 2006, 10, 174-196.
84. Qian, D. Z.; Kato, Y.; Shabbeer, S.; Wei, Y.; Verheul, H. M.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589, Clin. Cancer. Res., 2006, 12, 634-642.
85. Shao, Y.; Gao, Z.; Marks, P. A.; Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors, Proc. Natl. Acad. Sci. U S A, 2004, 101, 18030-18035.
86. Sigalotti, L.; Covre, A.; Fratta, E.; Parisi, G.; Colizzi, F.; Rizzo, A.; Danielli, R.; Nicolay, H. J.; Coral, S.; Maio, M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies, J. Transl. Med., 2010, 8, 56.